128 related articles for article (PubMed ID: 9192980)
1. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
Volm M; Koomägi R; Mattern J; Stammler G
Br J Cancer; 1997; 75(12):1774-8. PubMed ID: 9192980
[TBL] [Abstract][Full Text] [Related]
2. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
Volm M; Koomägi R
Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
[TBL] [Abstract][Full Text] [Related]
3. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.
Komiya T; Hosono Y; Hirashima T; Masuda N; Yasumitsu T; Nakagawa K; Kikui M; Ohno A; Fukuoka M; Kawase I
Clin Cancer Res; 1997 Oct; 3(10):1831-5. PubMed ID: 9815570
[TBL] [Abstract][Full Text] [Related]
4. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: analysis of 427 cases.
Anton RC; Brown RW; Younes M; Gondo MM; Stephenson MA; Cagle PT
Hum Pathol; 1997 Sep; 28(9):1079-82. PubMed ID: 9308733
[TBL] [Abstract][Full Text] [Related]
5. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
[TBL] [Abstract][Full Text] [Related]
6. Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment.
Izquierdo-Garcia FM; Moreno-Mata N; Herranz-Aladro ML; Cañizares MA; Alvarez-Fernandez E
Histol Histopathol; 2010 Oct; 25(10):1287-95. PubMed ID: 20712013
[TBL] [Abstract][Full Text] [Related]
7. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer.
Ramnath N; Hernandez FJ; Tan DF; Huberman JA; Natarajan N; Beck AF; Hyland A; Todorov IT; Brooks JS; Bepler G
J Clin Oncol; 2001 Nov; 19(22):4259-66. PubMed ID: 11709570
[TBL] [Abstract][Full Text] [Related]
8. Differential expression and pathological significance of autocrine motility factor/glucose-6-phosphate isomerase expression in human lung carcinomas.
Dobashi Y; Watanabe H; Sato Y; Hirashima S; Yanagawa T; Matsubara H; Ooi A
J Pathol; 2006 Dec; 210(4):431-40. PubMed ID: 17029220
[TBL] [Abstract][Full Text] [Related]
9. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival.
Caputi M; Esposito V; Baldi A; De Luca A; Dean C; Signoriello G; Baldi F; Giordano A
Am J Respir Cell Mol Biol; 1998 Feb; 18(2):213-7. PubMed ID: 9476908
[TBL] [Abstract][Full Text] [Related]
10. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas.
Dobashi Y; Jiang SX; Shoji M; Morinaga S; Kameya T
J Pathol; 2003 Feb; 199(2):208-20. PubMed ID: 12533834
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer.
Kwa HB; Michalides RJ; Dijkman JH; Mooi WJ
Lung Cancer; 1996 Jun; 14(2-3):207-17. PubMed ID: 8794404
[TBL] [Abstract][Full Text] [Related]
12. [The prognostic value of cytokeratin 19 expression in non-small cell lung cancer].
Kosacka M; Jankowska R
Pneumonol Alergol Pol; 2007; 75(4):317-23. PubMed ID: 18080980
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 overexpression in primary hypopharyngeal carcinomas.
Masuda M; Hirakawa N; Nakashima T; Kuratomi Y; Komiyama S
Cancer; 1996 Aug; 78(3):390-5. PubMed ID: 8697381
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
Mitselou A; Batistatou A; Nakanishi Y; Hirohashi S; Vougiouklakis T; Charalabopoulos K
Histol Histopathol; 2010 Oct; 25(10):1257-67. PubMed ID: 20712010
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
Rades D; Setter C; Dahl O; Schild SE; Noack F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
[TBL] [Abstract][Full Text] [Related]
18. The expression of cyclins D1 and E in predicting short-term survival in squamous cell carcinoma of the lung.
Anton RC; Coffey DM; Gondo MM; Stephenson MA; Brown RW; Cagle PT
Mod Pathol; 2000 Nov; 13(11):1167-72. PubMed ID: 11106072
[TBL] [Abstract][Full Text] [Related]
19. Expression of AGR2 in non small cell lung cancer.
Fritzsche FR; Dahl E; Dankof A; Burkhardt M; Pahl S; Petersen I; Dietel M; Kristiansen G
Histol Histopathol; 2007 Jul; 22(7):703-8. PubMed ID: 17455144
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric analysis of c-myc oncoprotein in non-small-cell lung carcinoma: comparison with immunohistochemical results.
De Santis L; Mangili F; Sassi I; Di Rocco M; Rossi C; Cantaboni A
Anal Cell Pathol; 1995 Apr; 8(3):247-57. PubMed ID: 7547497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]